83-5969-62 IL23A, Risankizumab Biosimilar 5mg 592158
特徴
- Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) that is selective for interleukin 23 (IL-23).
- On April 23, 2019 it was approved by the FDA (as SKYRIZI) for the treatment of moderate-to-severe plaque psoriasis in adults who are clinically considered eligible for systemic therapy or phototherapy for psoriasis.Label This drug has been commercialized through collaboration between the German pharmaceutical company, Boehringer Ingelheim, and Abbvie.
- Applications:Suitable for use in Functional Assays.
- Other applications not tested.
- Recommended Dilution:Optimal dilutions to be determined by the researcher.
- Storage and Stability:May be stored at 4℃ for short-term only.
- Aliquot to avoid repeated freezing and thawing.
- Store at -20℃.
- Aliquots are stable for 12 months after receipt.
- For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
仕様
- Size：5mg
- 抗体種類：Mab
- 宿主：human
- Source Antibody：human
- Grade：Affinity Purified
- Purity：Purified by Protein A/G affinity chromatography. ≥95%. Endotoxin: ≤1EU/mg (LAL)
- Form：Supplied as a liquid in PBS. No preservative added.
- Specificity：Recognizes human IL23A.
- Isotype：IgG1,k
- Calc Crossreactivity：Hu
- Immunogen：Recombinant protein corresponding to human IL-23alpha, expressed in CHO cells.
- この商品は法規制を確認しておりません。(法規制によって販売できない場合もございます)
- 製品の仕様は予告なく変更になる場合がございます。最新仕様はメーカーホームページをご確認ください。
- 【試薬に関するお問合せ】
- アズワン株式会社 試薬・プロセス材料グループ
- TEL：06-6447-8641
- FAX：06-6447-8642
- E-mail：[email protected]
商品のバリエーション （サイズ違い・スペック違い・オプション品など）
| 商品イメージ | アズワン品番 商品名 |
|---|---|
|
83-5969-62
IL23A, Risankizumab Biosimilar 5mg
|
|
|
83-5969-61
IL23A, Risankizumab Biosimilar 1mg
|
|
|
83-5969-60
IL23A, Risankizumab Biosimilar 100ug
|
よくあるご質問（FAQ）
掲載カタログ情報
| 掲載カタログ名 | 掲載ページ |
|---|